Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease.

ABSTRACT:

Background

The majority of patients with Crohn's disease (CD) will not achieve endoscopic remission on current therapy. Addition of tofacitinib to biologics may improve remission rates.

Methods

We retrospectively assessed safety and clinical and endoscopic effectiveness of off-label tofacitinib and biologics for CD.

Results

We identified 19 patients treated with tofacitinib and a biologic for refractory CD between 2017 and 2019. Tofacitinib was added for luminal disease on colonoscopy (n = 13), luminal disease on capsule (n = 3), and pyoderma gangrenosum (n = 3). The mean age was 41.2 years (28-62), mean disease was duration 16.9 years (6-36), and prior exposure to biologics was a median of 4 (1-6). Mean treatment duration was 9.6 months (SD, 3.3). Adverse events (AEs

SUBMITTER: Lee SD 

PROVIDER: S-EPMC8804506 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature